Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party

被引：0

作者：

Gugliotta, Gabriele ^{[1
]}

Castagnetti, Fausto ^{[2
]}

Breccia, Massimo ^{[3
]}

D'Adda, Mariella ^{[4
]}

Stagno, Fabio ^{[5
]}

Levato, Luciano ^{[6
]}

Carella, Angelo Michele ^{[7
]}

Martino, Bruno ^{[8
]}

Tiribelli, Mario ^{[9
]}

Cambrin, Giovanna Rege ^{[10
]}

Gozzini, Antonella ^{[11
]}

Salvucci, Marzia ^{[12
]}

Cedrone, Michele ^{[13
]}

Trabacchi, Elena ^{[14
]}

Usala, Emilio ^{[15
]}

Scortechini, Anna Rita ^{[16
]}

Luciano, Luigia ^{[17
]}

Soverini, Simona ^{[18
]}

Alimena, Giuliana ^{[19
]}

Cavo, Michele ^{[20
]}

Martinelli, Giovanni ^{[21
]}

Pane, Fabrizio ^{[22
]}

Saglio, Giuseppe ^{[23
]}

Baccarani, Michele ^{[24
]}

Rosti, Gianantonio ^{[25
]}

机构：

[1] Univ Bologna, Inst Hematol L & A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[2] Univ Bologna, Inst Hematol L & A Seragnoli, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[3] Sapienza Univ, Div Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy

[4] ASST Spedali Civili Brescia, Div Hematol, Brescia, Italy

[5] Univ Catania, Chair Hematol, Catania, Italy

[6] AO Pugliese Ciaccio, Hematol Unit, Catanzaro, Italy

[7] IRCCS AOU San Martino IST, UO Hematol, Genoa, Italy

[8] AO Bianchi Melacrino Morelli, Hematol Unit, Reggio Di Calabria, Italy

[9] Azienda Osped Univ Udine, Div Hematol & BMT, Dept Expt & Clin Med Sci, Udine, Italy

[10] S Luigi Gonzaga Univ Hosp, Dept Clin & Biol Sci, Turin, Italy

[11] Careggi Univ Hosp, Hematol Unit, Florence, Italy

[12] S Maria Croci Hosp, Hematol Unit, Ravenna, Italy

[13] San Giovanni Addolorata Hosp, UOC Hematol, Rome, Italy

[14] Guglielmo da Saliceto Hosp, Hematol Unit, Piacenza, Italy

[15] A Businco Hosp, Hematol Unit, Cagliari, Italy

[16] Osped Riuniti Univ Hosp, Hematol Unit, Ancona, Italy

[17] Fed II Univ, Dept Biochem & Med Technol, Naples, Italy

[18] Univ Bologna, Inst Hematol L & A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[19] Sapienza Univ, Hematol Unit, Rome, Italy

[20] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[21] Univ Bologna, Inst Hematol L & A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[22] AOU Fed II Napoli, Hematol, Naples, Italy

[23] S Luigi Gonzaga Univ Hosp, Dept Hematol & Clin & Biol Sci, Turin, Italy

[24] Univ Bologna, Dept Hematol Oncol, Bologna, Italy

[25] Univ Bologna, Inst Hematol L & A Seragnoli, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.3068.3068

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3068

引用

页数：5

共 50 条

[41] Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)
Shoukier, Mahran
Kantarjian, Hagop M.
Jabbour, Elias
Quintas-Cardama, Alfonso
Estrov, Zeev
Kadia, Tapan
Borthakur, Gautam
Garcia-Manero, Guillermo
Kornblau, Steven M.
Burton, Elizabeth M.
O'Brien, Susan
Cortes, Jorge E.
BLOOD, 2011, 118 (21) : 1189 - 1189
[42] Molecular response in long-term monitoring of patients with chronic myelogenic leukemia (CML) on nilotinib therapy
Nikolova, Dragomira
Damyanova, Vera
Radinov, Atanas
Toncheva, Draga
BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2021, 35 (01) : 650 - 656
[43] Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
Lipton, Jeffrey H.
le Coutre, Philipp D.
Wang, Jim
Yang, Mindy
Szczudlo, Tomasz
Giles, Francis
BLOOD, 2008, 112 (11) : 1110 - 1110
[44] DECLINING ROLE OF DISEASE TRANSORMATION AS A CAUSE OF DEATH IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN EARLY CHRONIC PHASE: A LONG-TERM ANALYSIS BY THE GIMEMA CML WP
Castagnetti, F.
Gugliotta, G.
Breccia, M.
Specchia, G.
Intermesoli, T.
Iurlo, A.
Martino, B.
Binotto, G.
Cavazzini, F.
Abruzzese, E.
Stagno, F.
Leoni, P.
Ferrero, D.
Rege-Cambrin, G.
Bocchia, M.
Gherlinzoni, F.
Palandri, F.
Soverini, S.
Alimena, G.
Pane, F.
Martinelli, G.
Cavo, M.
Saglio, G.
Baccarani, M.
Rosti, G.
HAEMATOLOGICA, 2014, 99 : 73 - 73
[45] NILOTINIB 800 MG DAILY IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: 12-MONTHS RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY
Rosti, G.
Castagnetti, F.
Breccia, M.
Poerio, A.
Gugliotta, G.
Levato, L.
Palandri, F.
Capucci, A.
Tiribelli, M.
Stagno, F.
Marzocchi, G.
Luatti, S.
Amabile, M.
Zaccaria, A.
Alimena, G.
Pane, F.
Martinelli, G.
Saglio, G.
Baccarani, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 440 - 440
[46] PROJECTING THE LONG-TERM SURVIVAL OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP) RECEIVING NILOTINIB OR IMATINIB
Botteman, F.
Stephens, J.
Coombs, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 348 - 348
[47] PERFORMANCE OF EUTOS LONG TERM SURVIVAL (ELTS) SCORE AND EFFICACY OF FIRST LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: RESULTS OF THE CML ITALIAN MULTICENTER OBSERVATIONAL STUDY (CML-IT-MOS)
Pregno, P.
Stagno, F.
Breccia, M.
Castagnetti, F.
Bonifacio, M.
Capodanno, I.
Caocci, G.
Martino, B.
Di Renzo, N.
Pizzuti, M.
Lucia, E.
Crisa, E.
Gozzini, A.
Tiribelli, M.
Cambrin, G. Rege
Sica, S.
Galimberti, S.
Bergamaschi, M.
Levato, L.
Guarini, A.
Mazza, P.
Pastore, D.
Cascavilla, N.
Aguzzi, C.
Luciano, L.
Abruzzese, E.
Di Bona, E.
Lucchesi, A.
Falzetti, F.
La Barba, G.
Rupoli, S.
Guella, A.
Nicolosi, M.
Saccona, F.
Monagheddu, C.
Albano, F.
Pane, F.
Ciccone, G.
Rosti, G.
Baccarani, M.
Saglio, G.
Specchia, G.
HAEMATOLOGICA, 2019, 104 : 140 - 141
[48] The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis
Castagnetti, Fausto
Gugliotta, Gabriele
Breccia, Massimo
Specchia, Giorgina
Abruzzese, Elisabetta
Levato, Luciano
Cavazzini, Francesco
Iurlo, Alessandra
Stagno, Fabio
Ferrero, Dario
Porretto, Ferdinando
Martino, Bruno
Rupoli, Serena
Intermesoli, Tamara
Fava, Carmen
Palandri, Francesca
Venturi, Claudia
Soverini, Simona
Testoni, Nicoletta
Alimena, Giuliana
Pane, Fabrizio
Saglio, Giuseppe
Martinelli, Giovanni
Baccarani, Michele
Rosti, Gianantonio
BLOOD, 2012, 120 (21)
[49] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
Ottmann, O. G.
le Coutre, P.
Gattermann, N.
Hochhaus, A.
Bruemmendorf, T. H.
Kindler, T.
Duyster, J.
Al-Ali, H.
Lipton, J.
Wang, J.
Yang, M.
Szczudlo, T.
Giles, F.
ONKOLOGIE, 2010, 33 : 138 - 138
[50] Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
Gugliotta, Gabriele
Castagnetti, Fausto
Breccia, Massimo
Levato, Luciano
D'Adda, Mariella
Stagno, Fabio
Tiribelli, Mario
Salvucci, Marzia
Fava, Carmen
Martino, Bruno
Cedrone, Michele
Bocchia, Monica
Trabacchi, Elena
Cavazzini, Francesco
Usala, Emilio
Rossi, Antonella Russo
Bochicchio, Maria Teresa
Soverini, Simona
Alimena, Giuliana
Cavo, Michele
Pane, Fabrizio
Martinelli, Giovanni
Saglio, Giuseppe
Baccarani, Michele
Rosti, Gianantonio
HAEMATOLOGICA, 2015, 100 (09) : 1146 - 1150

← 1 2 3 4 5 →